Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free HCWB Stock Alerts

HCW Biologics (HCWB) Competitors

HCW Biologics logo
$1.32 +0.11 (+9.09%)
Closing price 04:00 PM Eastern
Extended Trading
$1.30 -0.02 (-1.21%)
As of 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HCWB vs. GOSS, ACTU, MIRA, ELUT, and KALA

Should you buy HCW Biologics stock or one of its competitors? MarketBeat compares HCW Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HCW Biologics include Gossamer Bio (GOSS), Actuate Therapeutics (ACTU), MIRA Pharmaceuticals (MIRA), Elutia (ELUT), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

How does HCW Biologics compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

HCW Biologics has a net margin of -34.73% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat HCW Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer Bio-324.82% N/A -96.10%
HCW Biologics -34.73%-486.87%-29.19%

Gossamer Bio currently has a consensus target price of $5.00, suggesting a potential upside of 2,718.49%. HCW Biologics has a consensus target price of $5.00, suggesting a potential upside of 278.79%. Given Gossamer Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Gossamer Bio is more favorable than HCW Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

HCW Biologics has lower revenue, but higher earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer Bio$55.54M0.75-$170.37M-$0.79N/A
HCW Biologics$50K189.02-$7.96M-$9.46N/A

In the previous week, HCW Biologics had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Gossamer Bio. HCW Biologics' average media sentiment score of 1.44 beat Gossamer Bio's score of 1.02 indicating that HCW Biologics is being referred to more favorably in the news media.

Company Overall Sentiment
Gossamer Bio Positive
HCW Biologics Positive

Gossamer Bio has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 7.2% of Gossamer Bio shares are owned by insiders. Comparatively, 9.1% of HCW Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

HCW Biologics beats Gossamer Bio on 9 of the 16 factors compared between the two stocks.

How does HCW Biologics compare to Actuate Therapeutics?

HCW Biologics (NASDAQ:HCWB) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Actuate Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Actuate Therapeutics' return on equity of -430.93% beat HCW Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
HCW Biologics-34.73% -486.87% -29.19%
Actuate Therapeutics N/A -430.93%-180.86%

HCW Biologics currently has a consensus price target of $5.00, indicating a potential upside of 278.79%. Actuate Therapeutics has a consensus price target of $17.50, indicating a potential upside of 779.40%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than HCW Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Actuate Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Actuate Therapeutics had 1 more articles in the media than HCW Biologics. MarketBeat recorded 3 mentions for Actuate Therapeutics and 2 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 1.44 beat Actuate Therapeutics' score of 0.62 indicating that HCW Biologics is being referred to more favorably in the media.

Company Overall Sentiment
HCW Biologics Positive
Actuate Therapeutics Positive

HCW Biologics has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HCW Biologics$50K189.02-$7.96M-$9.46N/A
Actuate TherapeuticsN/AN/A-$22.23M-$0.97N/A

3.0% of HCW Biologics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

HCW Biologics has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Summary

Actuate Therapeutics beats HCW Biologics on 8 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to MIRA Pharmaceuticals?

HCW Biologics (NASDAQ:HCWB) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

MIRA Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. MIRA Pharmaceuticals' return on equity of -140.82% beat HCW Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
HCW Biologics-34.73% -486.87% -29.19%
MIRA Pharmaceuticals N/A -140.82%-135.01%

HCW Biologics presently has a consensus target price of $5.00, indicating a potential upside of 278.79%. Given HCW Biologics' higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than MIRA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, HCW Biologics and HCW Biologics both had 2 articles in the media. HCW Biologics' average media sentiment score of 1.44 beat MIRA Pharmaceuticals' score of 0.47 indicating that HCW Biologics is being referred to more favorably in the media.

Company Overall Sentiment
HCW Biologics Positive
MIRA Pharmaceuticals Neutral

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HCW Biologics has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

HCW Biologics has higher revenue and earnings than MIRA Pharmaceuticals. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HCW Biologics$50K189.02-$7.96M-$9.46N/A
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.30N/A

Summary

HCW Biologics beats MIRA Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does HCW Biologics compare to Elutia?

HCW Biologics (NASDAQ:HCWB) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 27.6% of Elutia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HCW Biologics currently has a consensus price target of $5.00, indicating a potential upside of 278.79%. Elutia has a consensus price target of $6.00, indicating a potential upside of 527.22%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than HCW Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Elutia
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Elutia has a net margin of 312.09% compared to HCW Biologics' net margin of -34.73%. Elutia's return on equity of 0.00% beat HCW Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
HCW Biologics-34.73% -486.87% -29.19%
Elutia 312.09%N/A -53.97%

HCW Biologics has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Elutia has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

In the previous week, Elutia had 2 more articles in the media than HCW Biologics. MarketBeat recorded 4 mentions for Elutia and 2 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 1.44 beat Elutia's score of 0.96 indicating that HCW Biologics is being referred to more favorably in the media.

Company Overall Sentiment
HCW Biologics Positive
Elutia Positive

Elutia has higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HCW Biologics$50K189.02-$7.96M-$9.46N/A
Elutia$12.46M3.29$53.38M$0.861.11

Summary

Elutia beats HCW Biologics on 11 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to KALA BIO?

HCW Biologics (NASDAQ:HCWB) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

KALA BIO has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. HCW Biologics' return on equity of -486.87% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
HCW Biologics-34.73% -486.87% -29.19%
KALA BIO N/A -1,336.10%-94.85%

HCW Biologics presently has a consensus target price of $5.00, suggesting a potential upside of 278.79%. KALA BIO has a consensus target price of $1,018.75, suggesting a potential upside of 41,144.94%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than HCW Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, HCW Biologics and HCW Biologics both had 2 articles in the media. HCW Biologics' average media sentiment score of 1.44 beat KALA BIO's score of 0.44 indicating that HCW Biologics is being referred to more favorably in the media.

Company Overall Sentiment
HCW Biologics Positive
KALA BIO Neutral

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

HCW Biologics has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market.

HCW Biologics has higher revenue and earnings than KALA BIO. HCW Biologics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HCW Biologics$50K189.02-$7.96M-$9.46N/A
KALA BION/AN/A-$26.98M-$96.14N/A

Summary

HCW Biologics beats KALA BIO on 8 of the 12 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCWB vs. The Competition

Export
MetricHCW BiologicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.45M$3.38B$6.51B$11.99B
Dividend YieldN/A2.33%2.67%5.62%
P/E Ratio-0.1419.7924.2424.13
Price / Sales189.02174.46473.6884.94
Price / CashN/A120.2043.0554.72
Price / Book1.578.2110.496.82
Net Income-$7.96M$23.89M$3.56B$337.52M
7 Day Performance-19.02%-3.00%-2.02%-0.96%
1 Month Performance328.02%-1.64%0.66%1.68%
1 Year Performance-74.71%40.20%21.85%26.88%

HCW Biologics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCWB
HCW Biologics
3.8933 of 5 stars		$1.32
+9.1%		$5.00
+278.8%		-78.0%$9.45M$50KN/A40
GOSS
Gossamer Bio
2.7762 of 5 stars		$0.19
-5.9%		$5.00
+2,555.3%		-87.5%$44.19M$48.47MN/A180
ACTU
Actuate Therapeutics
2.2001 of 5 stars		$1.82
-3.2%		$17.50
+861.5%		-77.3%$43.55MN/AN/A10
MIRA
MIRA Pharmaceuticals
1.0448 of 5 stars		$1.01
-2.9%		N/A-21.6%$42.44MN/AN/A2
ELUT
Elutia
4.0538 of 5 stars		$0.99
-4.8%		$6.00
+506.0%		-47.7%$42.36M$12.29M1.15180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 6/11/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel